Bicalutamide
- Generic Name
- Bicalutamide
- Brand Names
- Casodex
- Drug Type
- Small Molecule
- Chemical Formula
- C18H14F4N2O4S
- CAS Number
- 90357-06-5
- Unique Ingredient Identifier
- A0Z3NAU9DP
- Background
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
- Indication
Bicalutamide is indicated in combination with a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of Stage D2 metastatic carcinoma of the prostate.
- Associated Conditions
- Metastatic stage D2 Prostatic carcinoma
- Associated Therapies
- -
TAK-700 in Castration Resistant Prostate Cancer
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Registration Number
- NCT01658527
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪Onze Lieve Vrouw Ziekenhuis, Aals, Belgium
🇧🇪AZ Groeninge Kortrijk - Campus Vercruysselaan, Kortrijck, Belgium
Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT01342367
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 375
- Registration Number
- NCT01288911
- Locations
- 🇷🇴
Site RO3042, Bucharest, RO, Romania
🇷🇴Site RO3039, Bucharest, RO, Romania
🇷🇴Site RO3035, Bucharest, Romania
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Conditions
- Stage IIA Prostate Cancer AJCC v7Recurrent Prostate CarcinomaStage I Prostate Cancer AJCC v7Stage IIB Prostate Cancer AJCC v7Stage III Prostate Cancer AJCC v7
- Interventions
- Drug: Akt Inhibitor MK2206Drug: BicalutamideOther: Clinical ObservationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 108
- Registration Number
- NCT01251861
- Locations
- 🇺🇸
Bixby Medical Center, Adrian, Michigan, United States
🇺🇸Hickman Cancer Center, Adrian, Michigan, United States
🇺🇸Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: DocetaxelDrug: DexamethasoneDrug: EstramustineDrug: ZoladexDrug: CasodexProcedure: Radical Prostatectomy
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 28
- Registration Number
- NCT01250717
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
- Conditions
- Recurrent Prostate CancerStage IV Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT01200810
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
- Conditions
- Recurrent Prostate CarcinomaStage IV Prostate CancerProstate Adenocarcinoma
- Interventions
- Drug: BicalutamideBiological: CixutumumabDrug: Goserelin AcetateOther: Laboratory Biomarker AnalysisDrug: Leuprolide AcetateOther: Pharmacological Study
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 211
- Registration Number
- NCT01120236
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Highlands Oncology Group-Rogers, Rogers, Arkansas, United States
Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer
- Conditions
- Stage IV Prostate CancerProstate CancerHormone-resistant Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT01050842
- Locations
- 🇺🇸
Mayo Clinic In Arizona, Scottsdale, Arizona, United States
Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet in Healthy Subjects Under Fed Conditions
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Kremers Urban Development Company
- Target Recruit Count
- 60
- Registration Number
- NCT01044706
- Locations
- 🇨🇦
SFBC Anapharm, sainte-Foy, Quebec, Canada
Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting Conditions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2009-09-09
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 60
- Registration Number
- NCT00973050
- Locations
- 🇨🇦
Anapharm Inc., Sainte-Foy, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.